91
Participants
Start Date
February 28, 2015
Primary Completion Date
November 30, 2016
Study Completion Date
November 30, 2016
Sarilumab
Pharmaceutical form:solution
Sulfasalazine
Pharmaceutical form: Tablet Route of administration: Oral
Leflunomide
Pharmaceutical form: Tablet Route of administration: Oral
Bucillamine
Pharmaceutical form: Tablet Route of administration: Oral
Tacrolimus
Pharmaceutical form: Capsule Route of administration: Oral
Mizoribine
Pharmaceutical form: Tablet Route of administration: Oral
Investigational Site Number 392010, Asahi-Shi
Investigational Site Number 392001, Asahikawa-Shi
Investigational Site Number 392070, Beppu-Shi
Investigational Site Number 392036, Chiba
Investigational Site Number 392083, Chūōku
Investigational Site Number 392004, Fukui-shi
Investigational Site Number 392039, Fukuoka
Investigational Site Number 392030, Ichinomiya-Shi
Investigational Site Number 392002, Iizuka-Shi
Investigational Site Number 392019, Kagoshima
Investigational Site Number 392066, Kamakura-Shi
Investigational Site Number 392050, Kato-Shi
Investigational Site Number 392037, Kawachi-Nagano-Shi
Investigational Site Number 392099, Kawasaki-Shi
Investigational Site Number 392013, Kitakyushu-Shi
Investigational Site Number 392097, Kochi
Investigational Site Number 392065, Kushiro
Investigational Site Number 392026, Matsuyama
Investigational Site Number 392034, Miyagi-Gun
Investigational Site Number 392076, Nagoya
Investigational Site Number 392080, Nagoya
Investigational Site Number 392046, Narashino-Shi
Investigational Site Number 392062, Okayama
Investigational Site Number 392027, Osaki-Shi
Investigational Site Number 392059, Ōita
Investigational Site Number 392049, Sagamihara-Shi
Investigational Site Number 392014, Sapporo
Investigational Site Number 392041, Sapporo
Investigational Site Number 392073, Sapporo
Investigational Site Number 392006, Sasebo-Shi
Investigational Site Number 392021, Sendai
Investigational Site Number 392022, Sendai
Investigational Site Number 392033, Sendai
Investigational Site Number 392071, Sendai
Investigational Site Number 392029, Shizuoka
Investigational Site Number 392023, Takaoka-Shi
Investigational Site Number 392003, Tomakomai-Shi
Investigational Site Number 392074, Urasoe-Shi
Investigational Site Number 392079, Urayasu-Shi
Investigational Site Number 392048, Yokohama
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY